SMC - June 2024 decisions

10 June 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - May 2024 decisions

13 May 2024 - The SMC has today published advice on two medicines. ...

Read more →

NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19

9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...

Read more →

SMC - April 2024 decisions

8 April 2024 - The SMC has today published advice on seven medicines. ...

Read more →

SMC - March 2024 decisions

11 March 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - February 2024 decisions

12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

Updates on NICE and SMC collaboration on MTA for cystic fibrosis

1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...

Read more →

NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19

18 January 2024 - Draft guidance for public consultation has been published by NICE. ...

Read more →

SMC - January 2024 decisions

15 January 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - December 2023 decisions

11 December 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - November 2023 decisions

13 November 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Lynparza (olaparib) accepted for use in Scotland as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer

9 October 2023 - First and only approved medicine in Scotland which targets germline (hereditary) BRCA mutations in early breast cancer ...

Read more →

AbbVie’s Aquipta (atogepant) is now available in Scotland for the prevention of migraines in adults

9 October 2023 - The SMC has accepted Aquipta (atogepant), the oral, once daily calcitonin gene-related peptide receptor antagonist for restricted ...

Read more →

SMC - October 2023 decisions

9 October 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - September 2023 decisions

11 September 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →